Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01508221 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis
A Phase 2 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01508221: Completed Phase 2 study, sponsored by University of Cincinnati.
NCT01508221 is a Phase 2 study that has completed, run by University of Cincinnati. The registered enrollment target is 31 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01508221, a Phase 2 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the use of Trental and Vitamin E can help reduce the incidence of radiation necrosis (a lesion that usually occurs at the original tumor site) after radiosurgery. These two drugs are commonly used to treat radiation necrosis when it occurs but the hope is that these drugs can be used to prevent radiation necrosis from ever occurring.
Primary Outcome
Number of symptomatic death of healthy tissue caused by radiation therapy.
Interventions
- DIETARY_SUPPLEMENT Vitamin E
- DRUG Trental
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2011-06 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 2 |
What the finished NCT01508221 record still lists
NCT01508221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Vitamin E is the first listed.
NCT01508221 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01508221 about?
NCT01508221 is a clinical study titled "Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis". The purpose of this study is to determine whether the use of Trental and Vitamin E can help reduce the incidence of radiation necrosis (a lesion that usually occurs at the original tumor site) after radiosurgery. These two drugs are commonly used to treat radiation necrosis when it occurs but the ho...
What is the current status of trial NCT01508221?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2011-06. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT01508221?
The interventions under investigation include: Vitamin E (DIETARY_SUPPLEMENT), Trental (DRUG).
Who is sponsoring clinical trial NCT01508221?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01508221's enrollment target sits among peer trials
31 1578th of 2000 higher than 419 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia